Last reviewed · How we verify
LCAR-AIO T cells
At a glance
| Generic name | LCAR-AIO T cells |
|---|---|
| Sponsor | Nanjing Legend Biotech Co. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune Diseases (EARLY_PHASE1)
- A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases (PHASE1)
- A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LCAR-AIO T cells CI brief — competitive landscape report
- LCAR-AIO T cells updates RSS · CI watch RSS
- Nanjing Legend Biotech Co. portfolio CI